Clinical Practices that can Combat Endemic Legal Opioid Dependence: Genetic Addiction Risk Score (GARS™), KB220Z™, Comprehensive Analysis of Reported Drugs (CARD) and Electrotherapy

Blum K1,2,3,4,*, Febo M5, Giordano J6, Hauser M7, Oscar-Berman M7, Smolen A8, Simpatico T9, McLaughlin T10, Dinubile N11 and Roy K12

1Department of Psychiatry and McKnight Brain Institute, University of Florida, College of Medicine, Gainesville, Florida, USA
2Department of Neurogenomics, IGENE, LLC, Austin, Texas
3Department of Psychiatry, Boston University School of Medicine, and VA system, Boston, MA, USA
4Department of Behavioral genetics, University of Colorado, Boulder, Colorado
5Department of Psychiatry, Human Integrated Services Unit University of Vermont Center for Clinical and Translational Science, College of Medicine, Burlington, VT, USA
6Institute of Behavioral genetics, University of Colorado, Boulder, Colorado
7Department of Addiction research and Therapy, Malibu Beach Recovery Center, Malibu Beach, California
8Path Foundation NY, New York, New York, USA
9Center for Psychiatric Medicine, North Andover, Massachusetts, USA
10Department of Orthopaedic Surgery at the University of Pennsylvania, Philidelphia, Pennsylvania, USA
11Department of Addiction research a and Therapy, Malibu Beach Recovery Center, Malibu Beach, California
12Addiction Recovery Resources, Inc., New Orleans, Louisiana, USA, Genomics HealthCare, LLC, Montebello, California, USA

Iatrogenic prescription drug abuse in the United States caused ~27,000 unintentional drug overdose deaths back in 2007 when 9 million individuals reported chronic use of opioid pain treatment [1,2]. The Reward Deficiency Syndrome (RDS) presented here brings together research into strategies being developed for clinicians to assist in avoidance of some of the unintended consequences of opioid pain treatment. Genetic mechanisms in the prefrontal cortex (PFC) and the mesolimbic “reward center” have a role in the moderation of pain sensitivity and tolerance and can be used to determine genetic addiction predisposition [3]. Patients at risk would benefit from non-addictive alternative treatments for pain and careful monitoring.

A pilot study of genetic addiction risk score (GARS) severity was conducted in 70 patients attending two independent addiction treatment centers. The percentage of prevalence of the risk alleles (DRD2=A1; DRD3 =Gly; DRD4= 3R or 7R; SLC6A3 (DAT) =10R; 5HTTLPR = L or LA; OPRM1 = G; GABA 3 =181; MAO= 3R; and COMT=G) was calculated and an arbitrary severity score established based on the percentage of risk alleles present. Physiological “mechanisms of action” of H-Wave device stimulation (HWDS) have been investigated in animals and assessed in a recent meta-analysis. A natural dopaminergic agonist (KB220Z) has been evaluated using alternative KB200Z was engendered by the identification of the genetic therapeutic targets associated with Reward Deficiency Syndrome (RDS) [7]. This non-narcotic pharmacogenomic dopamine agonist can treat pain, improve pain tolerance and cognition, reduce craving and promote compliance [3]. Currently, we are under taking neuroimaging studies of KB220Z in rodents and an analysis of genetic risk for RDS in patients presenting with pain with and without associated RDS behaviors (n~400). A positive association will support the incorporation of genotyping of pain patients, at entry, for opiate addiction risk. To reduce addiction morbidity and mortality in pain treatment we propose a RDS: genetic testing for both narcotic metabolism and risk, non-addicting treatment alternatives; electrotherapy, dopaminergic activation KB220Z, careful monitoring and documentation of compliance and abstinence CARD coupled with the Revised Screener and Opioid Assessment (SOAPP-R) [8].

Conflict of Interest

Kenneth Blum, PhD is the holder of a number of patents involved with genetic testing and nutrigenomics and is currently- Managing Partner of IGENE, LLC and owns shares in Impact Genomics, Inc. the exclusive worldwide distributors of the GARS test and KB220Z respectively. He is a consultant Chief Scientific officer of G and G Healthcare Services LLC and Genomics Healthcare, LLC. He is on the Advisory Board of Dominon Diagnostics, LLC, Malibu Beach Recovery Center, Path Foundation, NY. He receives grants from Life Extension Foundation to Path Foundation. Mary Hauser is vice President of Dominion Diagnostics the commercial developer with IGENE LLC for the GARS test. Thomas Simpatico is on the Advisory Board of Dominion Diagnostics. Both Dr. Blum and Dr. Dinubile are paid consultants of Electronic Waveform Labs Huntington, Beach, California. No other conflict of interest.

*Corresponding author: Kenneth Blum, Department of Psychiatry and McKnight Brain Institute, University of Florida, College of Medicine, Gainesville, Florida, USA, E-mail: drd2gene@gmail.com

Received August 02, 2013; Accepted August 02, 2013; Published August 05, 2013


Copyright: © 2013 Blum K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Acknowledgement

Dr. Marcelo Febo is the recipient of NIH_NIDA Grant # DA019946. Dr. Kenneth Blum is the recipient of Life Extension Foundation grand to Path Foundation NY.

References